市場調查報告書

韋斯特症候群:流行病學的預測 (2030年)

West Syndrome - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955872
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
韋斯特症候群:流行病學的預測 (2030年) West Syndrome - Epidemiology Forecast - 2030
出版日期: 2020年06月01日內容資訊: 英文 100 Pages
簡介

全球主要7個國家的韋斯特症候群的已受診患病人數,2017年時刻達到了總合8057人。其中,美國國內的已受診患病人數為3999人,其中男性是2399人,女性是1600人。歐洲主要5個國家(EU5)的場合,法國最多 (737人),其次是英國 (684人),西班牙最少(445人)。日本的已受診患病人數為1090人。

本報告提供全球主要7個國家 - 美國,歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國) 、日本 - 的韋斯特症候群(癲癇性痙攣)的疫情趨勢與今後的預測 (2017∼2030年) 分析著。

目錄

第1章 主要洞察

第2章 韋斯特症候群概要

第3章 韋斯特症候群:摘要整理

第4章 韋斯特症候群:疾病的背景和概要

  • 簡介
  • 韋斯特症候群的代謝性病因
  • 韋斯特症候群:各病因的分類
  • 疾病和風險因素
  • 臨床症狀
  • 症狀
  • 病理生理學
  • 診斷
  • 鑑別診斷
  • 預後

第5章 韋斯特症候群的診斷演算法

第6章 癲癇性痙攣 (嬰兒痙攣)的臨床演算法:Texas Children's Hospital的案例

第7章 流行病學和患者人口

  • 主要調查結果
  • 韋斯特症候群的患病者總數 (主要7個國家的情況)
  • 韋斯特症候群的已受診患者總數 (主要7個國家的情況)

第8章 韋斯特症候群:各國流行病學的趨勢

  • 前提條件與根據:主要7個國家的情況
  • 美國
    • 前提條件與根據
    • 韋斯特症候群的患病人數
    • 韋斯特症候群的已受診患病人數
    • 韋斯特症候群的已受診患病人數:男女
  • (EU5歐洲主要5個國家)
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1009

DelveInsight's 'West Syndrome - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted West Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

West Syndrome Understanding

West syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. Usually, West syndrome consists of a characteristic triad: infantile spasms, the arrest of psychomotor development, and hypsarrhythmia, although one element may be missing. Spasms may be flexor, extensor, lightning, or nods, but most commonly they are mixed. Onset peaks are observed between the ages of 4-7 months and always occur before the age of 1 year. Also, boys are more commonly affected, and the prognosis is generally poor.

West syndrome may be separated into two groups: the symptomatic group, which is characterized by previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or by a known etiology, and the smaller, cryptogenic group that is characterized by a lack of previous signs of brain damage and known etiology. The prognosis appears to be partly based on early therapy with adrenocorticotropic hormone or oral steroids. Besides, the ILAE new diagnostic scheme classifies West syndrome amongst 'epileptic encephalopathies' and prefers 'epileptic spasms' rather than 'infantile spasms'.

It is a constellation of symptoms which are characterized by epileptic or infantile spasms, abnormal pattern of brain waves called hypsarrhythmia, and mental disability. The spasms that occur may range from violent jack-knife or "salaam" movements where the entire body bends in half, or they may change as little as a slight twitching of the shoulder or eye. These spasms usually start in the early months after birth, and medication can sometimes be used to help. They can also occur in elderly patients; they are called "epileptic spasms" rather than infantile spasms if this occurs.

West Syndrome Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of West Syndrome, Diagnosed Prevalent Population of west Syndrome and Gender-specific Diagnosed Prevalence of West Syndrome in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

West Syndrome Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of West Syndrome in the 7 major markets was found to be 8,057 in 2017.
  • In the United States, the diagnosed prevalent cases of West Syndrome was found to be 3,999 in 2017.
  • Delvelnsight has also analyzed gender-specific data for West Syndrome, which clearly suggests that it is more prevalent among males than females. It was found that in the United States the number of cases of West Syndrome in males and females were 2,399 and 1,600 respectively in 2017.
  • In the EU5 countries the diagnosed prevalence of West Syndrome was found to be maximum in France with 737 cases, followed by the United Kingdom with 684 cases in 2017. While, the least number of cases were found in Spain, with 445 cases in 2017.
  • In Japan, the diagnosed prevalence of West Syndrome was found to be 1,090 in 2017.

Scope of the Report:

  • The report covers the descriptive overview of West Syndrome, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of West Syndrome.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of West Syndrome, Total Diagnosed and Treated Cases of West Syndrome.

Report Highlights:

  • Eleven Year Forecast of West Syndrome
  • 7MM Coverage
  • Diagnosed Prevalent Population of West Syndrome
  • Report also covers Gender-specific diagnosed prevalence of West Syndrome, which clearly remarks a male preponderance and this finding maintains the hypothesis that male sex is a risk factor.
  • Expected launch of a potential therapies, Cannabidiol (CBD) oral solution (INSYS Therapeutics) and Epidiolex (GW Pharmaceuticals), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of West Syndrome.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of West Syndrome?
  • What is the historical West Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of West Syndrome at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to West Syndrome?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of West Syndrome during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The West Syndrome report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM West Syndrome market.
  • Quantify patient share distribution in the 7MM for West Syndrome.
  • The West Syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The West Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 West Syndrome Overview at a Glance

3 Executive Summary of West Syndrome

4 West Syndrome: Disease Background and Overview

  • 4.1 Introduction
  • 4.2 Metabolic etiologies in West syndrome
  • 4.3 Etiology-specific Subtypes of West syndrome
  • 4.4 Causes and Risk Factors
  • 4.5 Clinical Manifestations
  • 4.6 Symptoms
  • 4.7 Pathophysiology
  • 4.8 Diagnosis
  • 4.9 Differential Diagnosis
  • 4.10 Prognosis

5 Diagnostic Algorithm for West Syndrome

6 Clinical Algorithm for Epileptic Spasms (Infantile Spasms) By Texas Children's Hospital

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 7MM Total Prevalent Population of West Syndrome
  • 7.3 7MM Total Diagnosed Prevalent Population of West Syndrome

8 Country Wise-Epidemiology of West Syndrome

  • 8.1 Assumptions and Rationale: 7MM Countries
  • 8.2 United States
    • 8.2.1 Assumptions and Rationale
    • 8.2.2 Total Prevalent Population of West Syndrome in the United States
    • 8.2.3 Total Diagnosed Prevalent Population of West Syndrome in the United States
    • 8.2.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in the United States
  • 8.3 EU5 Countries
    • 8.3.1 Assumptions and Rationale
  • 8.4 Germany
    • 8.4.1 Total Prevalent Population of West Syndrome in Germany
    • 8.4.2 Total Diagnosed Prevalent Population of West Syndrome in Germany
    • 8.4.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany
  • 8.5 France
    • 8.5.1 Total Prevalent Population of West Syndrome in France
    • 8.5.2 Total Diagnosed Prevalent Population of West Syndrome in France
    • 8.5.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in France
  • 8.6 Italy
    • 8.6.1 Total Prevalent Population of West Syndrome in Italy
    • 8.6.2 Total Diagnosed Prevalent Population of West Syndrome in Italy
    • 8.6.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy
  • 8.7 Spain
    • 8.7.1 Total Prevalent Population of West Syndrome in Spain
    • 8.7.2 Total Diagnosed Prevalent Population of West Syndrome in Spain
    • 8.7.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain
  • 8.8 United Kingdom
    • 8.8.1 Total Prevalent Population of West Syndrome in the United Kingdom
    • 8.8.2 Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom
    • 8.8.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in the United Kingdom
  • 8.9 Japan
    • 8.9.1 Assumptions and Rationale
    • 8.9.2 Total Prevalent Population of West Syndrome in Japan
    • 8.9.3 Total Diagnosed Prevalent Population of West Syndrome in Japan
    • 8.9.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan

9 Appendix

  • 9.1 Bibliography
  • 9.2 Report Methodology

10 DelveInsight Capabilities

11 Disclaimer

12 About DelveInsight

List of Tables

  • Table 1: Summary of West Syndrome, Epidemiology and Key Events (2017-2030)
  • Table 2: Metabolic etiologies in Infantile Spasms
  • Table 3: Proportion of occurrence of different symptoms in West Syndrome patients
  • Table 4: Examinations to be conducted for West Syndrome
  • Table 5: Differential Diagnosis for Infantile spasms
  • Table 6: Total Prevalent Population of West Syndrome in the 7MM (2017-2030)
  • Table 7: Total Diagnosed Prevalent Population of West Syndrome in the 7MM (2017-2030)
  • Table 8: Total Prevalent Population of West Syndrome in the United States (2017-2030)
  • Table 9: Total Diagnosed Prevalent Population of West Syndrome in the United States (2017-2030)
  • Table 10: Gender-specific Diagnosed Prevalent Population of West Syndrome in the United States (2017-2030)
  • Table 11: Total Prevalent Population of West Syndrome in Germany (2017-2030)
  • Table 12: Total Diagnosed Prevalent Population of West Syndrome in Germany (2017-2030)
  • Table 13: Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany (2017-2030)
  • Table 14: Total Prevalent Population of West Syndrome in France (2017-2030)
  • Table 15: Total Diagnosed Prevalent Population of West Syndrome in France (2017-2030)
  • Table 16: Gender-specific Diagnosed Prevalent Population of West Syndrome in France (2017-2030)
  • Table 17: Total Prevalent Population of West Syndrome in Italy (2017-2030)
  • Table 18: Total Diagnosed Prevalent Population of West Syndrome in Italy (2017-2030)
  • Table 19: Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy (2017-2030)
  • Table 20: Total Prevalent Population of West Syndrome in Spain (2017-2030)
  • Table 21: Total Diagnosed Prevalent Population of West Syndrome in Spain (2017-2030)
  • Table 22: Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain (2017-2030)
  • Table 23: Total Prevalent Population of West Syndrome in the United Kingdom (2017-2030)
  • Table 24: Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017-2030)
  • Table 25: Gender-specific Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017-2030)
  • Table 26: Total Prevalent Population of West Syndrome in the Japan (2017-2030)
  • Table 27: Total Diagnosed Prevalent Population of West Syndrome in Japan (2017-2030)
  • Table 28: Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan (2017-2030)

List of Figures

  • Figure 1: Key Causes of West Syndrome
  • Figure 2: Symptoms of West Syndrome
  • Figure 3: Main characteristic symptoms of West Syndrome
  • Figure 4: Diagnostic Algorithm for West Syndrome
  • Figure 5: Clinical Algorithm for Epileptic Spasms (Infantile Spasms)
  • Figure 6: Total Prevalent Population of West Syndrome in the 7MM (2017-2030)
  • Figure 7: Total Diagnosed Prevalent Population of West Syndrome in the 7MM (2017-2030)
  • Figure 8: Total Prevalent Population of West Syndrome in the United States (2017-2030)
  • Figure 9: Total Diagnosed Prevalent Population of West Syndrome in the United States (2017-2030)
  • Figure 10: Gender-specific Diagnosed Prevalent Population of West Syndrome in the US (2017-2030)
  • Figure 11: Total Prevalent Population of West Syndrome in Germany (2017-2030)
  • Figure 12: Total Diagnosed Prevalent Population of West Syndrome in Germany (2017-2030)
  • Figure 13: Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany (2017-2030)
  • Figure 14: Total Prevalent Population of West Syndrome in France (2017-2030)
  • Figure 15: Total Diagnosed Prevalent Population of West Syndrome in France (2017-2030)
  • Figure 16: Gender-specific Diagnosed Prevalent Population of West Syndrome in France (2017-2030)
  • Figure 17: Total Prevalent Population of West Syndrome in Italy (2017-2030)
  • Figure 18: Total Diagnosed Prevalent Population of West Syndrome in Italy (2017-2030)
  • Figure 19: Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy (2017-2030)
  • Figure 20: Total Prevalent Population of West Syndrome in Spain (2017-2030)
  • Figure 21: Total Diagnosed Prevalent Population of West Syndrome in Spain (2017-2030)
  • Figure 22: Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain (2017-2030)
  • Figure 23: Total Prevalent Population of West Syndrome in the United Kingdom (2017-2030)
  • Figure 24: Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017-2030)
  • Figure 25: Gender-specific Diagnosed Prevalent Population of West Syndrome in the UK (2017-2030)
  • Figure 26: Total Prevalent Population of West Syndrome in Japan (2017-2030)
  • Figure 27: Total Diagnosed Prevalent Population of West Syndrome in Japan (2017-2030)
  • Figure 28: Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan (2017-2030)